Abstract
New Options in ADPKD and How to Use themÃÆâÃâââ¬Ãâââ¬Åthe PROPKD Score and Beyond
In recent years we have not only learned about new therapy options to slow down cyst growth in ADPKD. PROPKD, a progression score which combines clinical with genetic data, has been validated, which is a tool for the nephrologist in making individual clinical decisions in favour or against (potentially harmful) long-term medications. Patient cohorts have been characterized in whom kidney size remains stable at a certain plateau for years. This article reviews the literature on these new options and discusses possible adjustments of the PROPKD score and treatment options specifically for East Asian patients. Also, a practical concept for the clinic is proposed regarding the best management of CKD patients with ADPKD, making use of the progression score and pharmacogenetic information.
Author(s):
Hasjog Rote
Abstract | Full-Text | PDF
Share this
Google scholar citation report
Citations : 387
Journal of Clinical & Experimental Nephrology received 387 citations as per google scholar report
Abstracted/Indexed in
- Google Scholar
- Sherpa Romeo
- China National Knowledge Infrastructure (CNKI)
- Directory of Research Journal Indexing (DRJI)
- WorldCat
- Publons
- Secret Search Engine Labs
Open Access Journals
- Aquaculture & Veterinary Science
- Chemistry & Chemical Sciences
- Clinical Sciences
- Engineering
- General Science
- Genetics & Molecular Biology
- Health Care & Nursing
- Immunology & Microbiology
- Materials Science
- Mathematics & Physics
- Medical Sciences
- Neurology & Psychiatry
- Oncology & Cancer Science
- Pharmaceutical Sciences